Angraal S, et al. - Data regarding national-level trends of digoxin use and hospitalization for toxicity is not sufficiently known, and guidelines for its use have changed. Thus, researchers conducted a cohort study at the population-level involving patients aged ≥ 65 years to identify and describe digoxin prescription trends. To that end, they used data from IQVIA, Inc.’s National Prescription Audit (2007–2014). They also evaluated temporal trends of hospitalizations linked with digoxin toxicity in a national cohort of Medicare fee-for-service beneficiaries over 65 years of age. In all, they noted a decline from 8,099,856 to 4,343,735 in the number of digoxin prescription from 2007 through 2014. Among Medicare fee-for-service beneficiaries, a marked alleviation in 30-day and in-hospital mortality rates linked with hospitalization for digoxin toxicity was observed—from 14.0% to 10.1% and from 6.0% to 3.7%, respectively. Despite the reduction in digoxin prescriptions, its widespread use has not stopped. However, patients admitted for digoxin toxicity, as well as harmful effects linked with these hospitalizations, have decreased.